Qi L - Search Results

1

A pan-cancer single-cell panorama of human natural killer cells.

Tang F, Li J, Qi L, Liu D, Bo Y, Qin S, Miao Y, Yu K, Hou W, Li J, Peng J, Tian Z, Zhu L, Peng H, Wang D, Zhang Z. Tang F, et al. Among authors: qi l. Cell. 2023 Sep 14;186(19):4235-4251.e20. doi: 10.1016/j.cell.2023.07.034. Epub 2023 Aug 21. Cell. 2023. PMID: 37607536 Free article.

2

A Novel Purine and Uric Metabolism Signature Predicting the Prognosis of Hepatocellular Carcinoma.

Yang S, Zhang B, Tan W, Qi L, Ma X, Wang X. Yang S, et al. Among authors: qi l. Front Genet. 2022 Jul 12;13:942267. doi: 10.3389/fgene.2022.942267. eCollection 2022. Front Genet. 2022. PMID: 35903353 Free PMC article.

3

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials.

Liu X, Fang Y, Li Y, Li Y, Qi L, Wang X. Liu X, et al. Among authors: qi l. Front Oncol. 2022 Sep 28;12:894861. doi: 10.3389/fonc.2022.894861. eCollection 2022. Front Oncol. 2022. PMID: 36249045 Free PMC article.

4

Promoting proliferation and tumorigenesis of breast cancer: KCND2's significance as a prognostic factor.

Yang S, Zhou P, Qi L, Wang Y, Li Y, Wang X. Yang S, et al. Among authors: qi l. Funct Integr Genomics. 2023 Jul 31;23(3):257. doi: 10.1007/s10142-023-01183-0. Funct Integr Genomics. 2023. PMID: 37522982

5

Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study.

Li Y, Qi L, Wang Y, Zhao X, Lv S, Feng Y, Liu C, Li P, Xiong B, Guo Y, Lv D, Liu Y, Mao T, Yuan K, Cheng X, Li Y, Wang X. Li Y, et al. Among authors: qi l. Anticancer Drugs. 2023 Jul 1;34(6):763-774. doi: 10.1097/CAD.0000000000001456. Epub 2022 Nov 19. Anticancer Drugs. 2023. PMID: 36730296 Clinical Trial.

6

Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid^® capsule in healthy Chinese males.

Wang J, Qi L, Wang Z, Chen G, Liu C, Liu Y, Liu X, Wang Y, Lei C, Wang X. Wang J, et al. Among authors: qi l. Cancer Chemother Pharmacol. 2018 Jul;82(1):159-164. doi: 10.1007/s00280-018-3604-x. Epub 2018 Jun 11. Cancer Chemother Pharmacol. 2018. PMID: 29926217 Clinical Trial.

7

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.

Wang J, Qi L, Liu L, Wang Z, Chen G, Wang Y, Liu X, Liu Y, Liu H, Tong Y, Liu C, Lei C, Wang X. Wang J, et al. Among authors: qi l. Front Pharmacol. 2019 Aug 15;10:905. doi: 10.3389/fphar.2019.00905. eCollection 2019. Front Pharmacol. 2019. PMID: 31474863 Free PMC article.

8

Tandem enrichment of serum exosomes and exosomal RNA with titanium dioxide.

Zhang B, Li H, Kong L, Yang N, Yang S, Qi L, Liu T, Wang X, Qin W. Zhang B, et al. Among authors: qi l. J Chromatogr A. 2023 Mar 29;1693:463882. doi: 10.1016/j.chroma.2023.463882. Epub 2023 Feb 21. J Chromatogr A. 2023. PMID: 36857982

9

Identification of a Group of Therapeutic Targets and Prognostic Biomarker for Triple Negative Breast Cancer.

Li Y, Yang S, Qi L, Li Y, Wang X. Li Y, et al. Among authors: qi l. Adv Ther. 2024 Apr;41(4):1621-1636. doi: 10.1007/s12325-024-02806-z. Epub 2024 Feb 29. Adv Ther. 2024. PMID: 38421558

10

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.

Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, Liu C, Bai H, Han C, Sun Y, Liu J. Wang X, et al. Among authors: qi l. J Cell Mol Med. 2021 Sep;25(17):8222-8228. doi: 10.1111/jcmm.16693. Epub 2021 Aug 4. J Cell Mol Med. 2021. PMID: 34346165 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,261 results

Search Page